BioNTech's co-founders, Ugur Sahin and Oezlem Tuereci, will leave the company by 2026 to establish a new venture focused on next-generation mRNA drugs. Although BioNTech's stock plummeted following ...

Organoids, assembloids, and organ-on-a-chip technologies represent transformative advances in the fields of drug discovery, precision medicine, and ...

Drug discovery is like molecular Tetris. Chemists snap atoms together, adjusting the pieces until everything fits, and ...

An update from Telescope Innovations Corp ( (TSE:TELI) ) is now available.

The session Next-Generation Drug Development Enabled by Automation, Digitalization, and AI/ML is scheduled to take place at Pittcon 2026 in San Antonio, TX, on Monday, March 9, from 8:30 am–10:40 am ...

AI revolutionizes pharma manufacturing by enhancing efficiency, quality, and cost-effectiveness. Key opportunities include predictive maintenance, real-time quality control, and supply chain ...

Here’s how drug developers can best approach interactions with the agency following last year’s seismic changes to its leadership, workforce and policies.

A blockbuster drug is a best-selling medication earning over $1 billion annually. Learn about them and how they revolutionize ...

PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic disease; ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Q4 2025 earnings call recap: pipeline milestones, PROTAC FDA/PDUFA timeline, 2026 data catalysts, and cash runway—read now.

Pfizer Inc. (NYSE: PFE) on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer announced that its Braftovi regimen demonstrated a statistically ...